ABUS compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

ABUSArbutus Biopharma Corp

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

ABUSArbutus Biopharma Corp

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ABUS 9

MRNAModernacustomer

ALNYAlnylam Pharmaceuticalscustomer

ASMBAssembly Biosciencessupplier

—Qilu Pharmaceuticalunlistedcustomer

5 more · ABUS chain ›

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

ABUSArbutus Biopharma Corp

4.01· pre 4.28· delayed

Mkt cap$791.4MRevenue$1MQ2 FY26Revenue$14MFY25

LLYELI Lilly & Co

1,418.01· pre 1,398.00· delayed

Pre-marketNov 3 '26delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Pre-marketNov 3 '26delayed

ABUSArbutus Biopharma Corp

LLYELI Lilly & Co

4.01pre 4.28delayed

Price

1,418.01pre 1,398.00delayed

$791.4M

Mkt cap

$1.3T

Q2 FY26$1M

Revenue

$24.4BQ3 FY26

FY25$14M

Revenue

$65.2BFY25

ABUS4.01vsLLY1,418.01Pre-marketNov 3 '26delayed